Welcome to our dedicated page for Cartesian Therapeutics SEC filings (Ticker: RNAC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cartesian Therapeutics, Inc. filings document the regulatory disclosures of a late clinical-stage biotechnology company developing cell therapy candidates for autoimmune diseases. Recent Form 8-K reports furnish quarterly and annual financial results, business updates, corporate slide presentations, and clinical disclosures for Descartes-08, including autoimmune indications such as generalized myasthenia gravis, myositis, juvenile dermatomyositis and systemic lupus erythematosus.
Proxy materials cover director elections, board committee service, executive compensation, equity awards and other governance matters. Additional 8-K filings report board changes and compensatory arrangements, while the company's disclosures also describe cash resources, FDA designations, forward-looking statements and equity incentive activity tied to its common stock.
Cartesian Therapeutics, Inc. reported a first-quarter 2026 net loss of $39.2 million, wider than the prior year, as it increased investment in its lead cell therapy programs and recorded a higher fair value for contingent value rights.
Revenue was minimal at $0.1 million, all from a government grant, with no collaboration revenue recognized. Research and development expenses rose to $19.5 million, driven mainly by Phase 3 work on Descartes-08 for myasthenia gravis, while general and administrative costs declined to $7.1 million.
The company ended the quarter with $120.4 million in cash, cash equivalents and restricted cash and raised about $14.6 million through an at-the-market stock offering, and believes this liquidity will fund planned operations for at least the next 12 months.
Cartesian Therapeutics reported first quarter 2026 results and updated progress on its Descartes-08 cell therapy pipeline. Cash, cash equivalents and restricted cash were $120.4 million as of March 31, 2026, which the company expects will fund planned operations into mid-2027, including completion of the ongoing Phase 3 AURORA trial in myasthenia gravis.
For the quarter, total revenues were $78 thousand versus $1.1 million a year earlier, while research and development expenses rose to $19.5 million from $14.7 million, and general and administrative expenses declined to $7.1 million from $8.3 million. Net loss widened to $39.2 million, or $1.46 per basic share, compared with $17.7 million, or $0.68 per basic share, in the prior-year period.
The company highlighted ongoing enrollment in the randomized, placebo-controlled Phase 3 AURORA trial of Descartes-08 in acetylcholine receptor antibody–positive myasthenia gravis, initiation of the Phase 2 TRITON trial in multi-refractory myositis, and enrollment of multiple patients in the pediatric Phase 1/2 HELIOS trial in juvenile dermatomyositis. Descartes-08 is an autologous BCMA-targeting CAR-T designed for outpatient administration without preconditioning chemotherapy and has received multiple U.S. FDA designations, including Orphan Drug and Regenerative Medicine Advanced Therapy designations in myasthenia gravis and Rare Pediatric Disease designation in juvenile dermatomyositis.
Cartesian Therapeutics, Inc. will hold its 2026 Annual Meeting virtually on June 12, 2026 at 10:00 a.m. Eastern Time. Stockholders will vote to elect three Class I directors to terms ending in 2029, approve on a non-binding basis executive compensation, and ratify Ernst & Young LLP as auditor for 2026.
Holders of 29,302,729 shares of common stock outstanding as of April 14, 2026 are entitled to one vote per share and may vote by internet, telephone, mail, or during the virtual meeting. The proxy also outlines board structure, committee responsibilities, and a pay program emphasizing variable, equity-based compensation tied to company performance.
Cartesian Therapeutics, Inc. insider reporting shows a trust-related conversion of preferred stock into common stock. On April 2, 2026, Seven One Eight Three Four Irrevocable Trust elected to convert a portion of its Series A Non-Voting Convertible Preferred Stock into 758,001 shares of common stock at a stated conversion price of $0.0000 per share, all held indirectly with Elizabeth Hoge acting as trustee.
Following the conversion, the Trust holds 5,313,261 shares of common stock and 33,662.224 shares of Series A Non-Voting Convertible Preferred Stock, with the remaining preferred shares subject to a beneficial ownership limitation. A separate indirect holding reflects 506,999 shares of common stock held by Hoge's spouse. Footnotes state these securities stem from merger consideration and a private placement completed in November 2023.
Cartesian Therapeutics, Inc. insider filing shows a trust converting preferred stock into common shares. On April 2, 2026, a trust for the benefit of Murat Kalayoglu’s spouse and children exercised 22,740.03 shares of Series A Non-Voting Convertible Preferred Stock to acquire 758,001 shares of common stock at a conversion price of $0.00 per share.
After the transaction, the trust held 33,662.224 shares of the preferred stock and 5,313,261 shares of common stock indirectly. Murat Kalayoglu also held 506,999 shares of common stock directly. The filing reflects a derivative exercise and conversion, not an open-market purchase or sale.
An investor group led by Murat Kalayoglu updated its ownership in Cartesian Therapeutics, Inc. common stock. The group now reports beneficial ownership of 5,833,971 shares, about 19.9% of the company’s common stock, based on 28,544,728 shares outstanding as of March 31, 2026.
On March 31, 2026, Murat Kalayoglu resigned from the board of directors. On April 2, 2026, a trust affiliated with him converted 22,740.030 shares of Series A Preferred Stock into 758,001 shares of common stock, contributing to the currently reported ownership levels across the reporting persons.
Cartesian Therapeutics, Inc. reported that board member Murat Kalayoglu, M.D., Ph.D. has informed the company he will resign from its Board of Directors, effective March 31, 2026, to pursue other opportunities.
He currently serves as Chairman of the Board’s Science and Technology Committee and as a member of the Nominating and Corporate Governance Committee, and will cease serving on these committees in connection with his resignation. The company states that his decision was not due to any disagreement with the company regarding its operations, policies, or practices and expresses appreciation for his service since 2023.
Cartesian Therapeutics director Michael Singer reported a bona fide gift of 6,555 shares of Common Stock on March 13, 2026. The gift was made at no stated price and is classified as a non-market disposition rather than a sale.
After the gift, Singer directly holds 49,578 shares. He also reports additional indirect holdings in Cartesian Therapeutics through several trusts, a spouse account, and custodial accounts for his children under UTMA.
Cartesian Therapeutics, Inc. disclosure: multiple Squarepoint entities report beneficial ownership stakes in Common Stock totaling between 30,949 and 2,209,601 shares per entity as filed on 03/09/2026.
The filing lists Squarepoint Ops LLC, Squarepoint Capital LLP, Squarepoint Operations Private Limited, and Squarepoint (DIFC) Ltd each holding 2,209,601 shares (reported 8.34% of the class), Squarepoint Master Fund Limited holding 2,178,652 shares (8.22%), and Squarepoint Core Master Fund Limited holding 30,949 shares (0.12%).
Cartesian Therapeutics, Inc. outlines its business as a late clinical-stage biotechnology company developing mRNA-engineered cell therapies for autoimmune diseases, led by Descartes-08.
Descartes-08, an autologous anti-BCMA mRNA CAR-T, is being advanced for generalized myasthenia gravis, myositis and juvenile dermatomyositis. It has Orphan Drug and RMAT designations for myasthenia gravis and Rare Pediatric Disease Designation for juvenile dermatomyositis. Phase 1/2 myasthenia gravis studies showed deep, durable symptom improvements over 12 months without observed cytokine release syndrome or neurotoxicity, supporting outpatient dosing without preconditioning chemotherapy.
The company has initiated a Phase 3 AURORA trial in acetylcholine receptor antibody–positive myasthenia gravis under a Special Protocol Assessment and is preparing randomized trials in myositis and a pediatric basket trial. Development of Descartes-08 in systemic lupus erythematosus and of next-generation CAR-T Descartes-15 in multiple myeloma has been paused to prioritize autoimmune indications. Cartesian highlights in-house cGMP manufacturing capacity in Frederick, Maryland, a growing global patent estate extending into the 2040s, and key license agreements with Biogen, the U.S. National Cancer Institute and Sobi.